Genmab Ready For European Zalutumumab Filing Based On PFS Data, Searching For A Partner To Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Indications are a regulatory filing for the EGFR inhibitor in second-line head and neck cancer would be acceptable in Europe, though not in the U.S., CEO vande Winkel says.